Key facts
- This page summarizes Wendy Carruthers's Form 4 filing for BOSTON SCIENTIFIC CORP (BSX).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 02 Jan 2024, 20:30.
Wendy Carruthers - 01 Jan 2024 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)
- Reporting relationship
- EVP, Human Resources
- Issuer ticker
- BSX
- Reported as of
- 01 Jan 2024
- Net transaction value
- -$311,018
- SEC form
- 4
- Accepted by SEC
- 02 Jan 2024, 20:30:18 UTC
- Prior SEC filing
- 18 Dec 2023
- Next SEC filing
- 08 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Susan Thompson, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Wendy Carruthers filed Form 4 for BOSTON SCIENTIFIC CORP (BSX) on 02 Jan 2024.
Change
- Previous filing in this sequence was filed on 18 Dec 2023.
- Current net transaction value: -$311,018.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BSX
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +11,772
- Change %
- +29%
- Price
- $0.000000
- Shares after
- 53,041
- Date
- 01 Jan 2024
- Ownership
- Direct
- Footnotes
- F1
BSX
transaction
Common Stock
Tax liability
- Transaction value
- $311,018
- Shares
- -5,380
- Change %
- -10%
- Price
- $57.81
- Shares after
- 47,661
- Date
- 01 Jan 2024
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BSX
transaction
Derivative
Performance Share Units
Options Exercise
- Transaction value
- $0
- Shares
- -11,772
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 01 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,772
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2023.
Footnote F2
Each performance shares unit represents the Company's commitment to issue one share of Boston Scientific common stock.